No matching results for ''
Tip: Try a valid symbol or a specific company name for relevant results
Work & Management
UK Markets open in 3 hrs 26 mins
Child Trust Fund
How to find your child's share of £9bn government money
Your child could have access to £1,500 worth of unclaimed funds, here is how you can track it down
Orphazyme A/S (ORPH)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
2,026 reactions on $ORPH conversation
Sign in to post a message.
🔴🔴🔴🔴🔴🔴🔴. The 12-month combined phase 2 and 3 trials (completed in Jan 2019) showed 80% reduction in NPC in the patients group. The 24-months extension trials (completed in Jan 2020) were even better, it showed 90% reduction in NPC. Drug was very well-telorated with very high safety results. FDA loves it. Given the orphan drug designation and fast track review, I am now 1000000% sure FDA will approve it 👍. SP will hit $80. 💪
Here's Why Orphazyme Shares Rocketed Higher on Wednesday? Source:
Jack B. Carroll
Highest short squeeze 99 outta 10,100 stocks and a short interest borrow rate of 125% with only 10,000 shares left to borrow. This is going to be big
Jack B. Carroll
Whoops: per Fintel squeeze alert is number 1 outta 10,000 stocks, and has a squeeze score of 99 and only 10,000 shares to ‘borrow’ with a borrow rate of125%
This might be the biggest play this year, with FDA approval. ORPH would take over market tomorrow.
Thomas from Denmark
logically this can explode like never seen before: you have the shorters on the run, you have the big buyer out there, you have the decision tomorrow. The sky is the limit today.
Well, guess I git skin in the game now...6K shares just fired off at $16. To the moon???
I have a hard time understanding who is selling now. I am in at around $ 10.15/share. I know some here have lower averages and some have drastically higher averages (this group cannot sell without major blood letting). For those with lower averages, haven't most of you already taken some profits? To me, it seems better to hang on for one or two more days and maximize the remaining return. Anyone care to share thoughts?
Low marketcap. Last week $77. Today $20. Tomorrow +$100 approval
Plenty of accumulation around the IPO price of $11 (last year). This is like buying a new company at IPO price before their first major FDA approval to be a monopoly in a $300M market.
$$44 tommorrow but holding for $250 with fda approval i think it can happen
if that study (ALS) failed they didn’t file to FDA but this one didn’t fail for NPC therefore should be ok if met the end point and efficacy is more than 50% and if it was 70% or more then win win. Anyone can help posting the outcome of the study please post your comments
🔴🔴🔴 Total of worldwide NPC patients is about 3,000. ORPH drug average annual cost per patient is $450K. This is $1.35B in annual sales. With CAGR of 42% per year, ORPH share price (in case of approval) could easily hit $50-$70.
Orphazyme doesn't have any reliable sources of revenue yet, but that could change any day now. On or before Jun. 17, 2021, the FDA is expected to issue an approval decision regarding an application for the company's lead candidate, arimoclomol. If given a green light, it will become the first treatment specifically approved for around 1,800 Americans with an ultra-rare lysosomal storage disorder called Neimann-Pick Disease Type C.
If approved, arimoclomol could end up competing with Zavesca, a drug from Johnson & Johnson (NYSE:JNJ) that is already approved to treat other lysosomal disorders. Back in 2010, the FDA refused to complete its review of Zavesca's active ingredient until it had more data that never materialized.
just heard of orph, is this still a buy? tomorrow fda decision correct? I heard ppl are saying it might be 80-90% fda approved, correct?
⭐ Top Bullish Charts | June 2021 💰💵📈
Someone brought 10k share 🙌🙏💵
Also, this is #1 shorted on short squeeze list for tomorrow they have 0 days left to cover 125% interest and pending FDA APPROVAL.
FDA website lists daily approvals... See below: scroll to bottom of page for latest approvals
".........Thomas Blaettler, Chief Medical Officer, commented, “We are highly encouraged by the 12-month results from our open-label extension study. Arimoclomol had a sustained effect on disease progression over two years. Furthermore, patients initially randomized to placebo in the placebo-controlled trial experienced a 90% reduction in disease progression when switched to arimoclomol treatment”......."
2 penny stocks to buy today
GB News hit by more than 350 complaints on launch night
Jeff Petry's absurdly bloodshot eyes are freaking people out
Yahoo Sports Canada
© 2021 Verizon Media. All rights reserved.
About our ads